OpGen
OpGen Q2 Revenues Fall 32 Percent
The decline was driven by the dissolution of the firm's FISH business and the completion of an R&D project at subsidiary Ares Genetics.
OpGen Q1 Revenues Rise 34 Percent on Combination With Curetis
OpGen said it is awaiting a clearance decision for its Unyvero pneumonia cartridge in China, where it is currently under review and pending approval.
OpGen Fourth Quarter Revenues Increase 64 Percent
The company's full-year revenues were $4.2 million, up 20 percent from the year-ago quarter.
OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval
The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators.
OpGen Enters $25M Direct Offering Agreement
A single healthcare-focused investor will purchase 2.78 million shares of common stock, 5.55 million prefunded warrants, and an additional 4.17 million shares of common stock.
Jan 13, 2021
OpGen Preliminary Q4 Revenue Climbs 63 Percent
Nov 24, 2020
OpGen Inks $10M Private Placement Agreement
Aug 20, 2020
OpGen Nabs CE-IVD Mark for SARS-CoV-2 Kit
Aug 12, 2020
OpGen Q2 Revenues Climb 20 Percent
Jul 15, 2020
OpGen Preliminary Q2 Revenues Increase 20 Percent
May 7, 2020
OpGen Q1 Revenues Drop 38 Percent
Apr 14, 2020
OpGen Q1 Preliminary Revenues Down 38 Percent
Mar 24, 2020
OpGen Fourth Quarter Revenues Increase 8 Percent
Feb 20, 2020
Curetis Preliminary 2019 Revenues Up 64 Percent
Feb 12, 2020